SS31, a small molecule antioxidant peptide, attenuates β-amyloid elevation, mitochondrial/synaptic deterioration and cognitive deficit in SAMP8 mice

Current Alzheimer Research

Volumn 13, Issue 3, 2016, Pages 297-306

  Jia, Yan Li ^a,b   Sun, Su Juan ^a   Chen, Jing Hong ^a   Jia, Qian ^a,b   Huo, Tian Tian ^a   Chu, Li Fang ^a,b   Bai, Jiang Tao ^a,b   Yu, Ye Jing ^a,b   Yan, Xiao Xin ^c   Wang, Jian Hua ^a  

^a HEBEI GENERAL HOSPITAL   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Alzheimer s disease; Amyloid pathology; Antioxidants; Mice; Mitochondria; Oxidative stress; Synaptic function

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BRAIN PROTEIN; CYCLOPHILIN D; DLP1 PROTEIN; ELAMIPRETIDE; FIS1 PROTEIN; MITOCHONDRIAL PROTEIN; MITOFUSIN 2; NEUROMODULIN; POSTSYNAPTIC DENSITY PROTEIN 95; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; ANTIOXIDANT; ARGINYL-2,'6'-DIMETHYLTYROSYL-LYSYL-PHENYLALANINAMIDE; OLIGOPEPTIDE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN MITOCHONDRION; CELL LYSATE; COGNITIVE DEFECT; CONTROLLED STUDY; ELECTRON MICROSCOPY; HIPPOCAMPAL CA1 REGION; HOMEOSTASIS; LEARNING DISORDER; MALE; MEMORY DISORDER; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE ACCELERATED MOUSE; SYNAPSE; AGING; ANIMAL; ANTAGONISTS AND INHIBITORS; COGNITION DISORDERS; DRUG EFFECTS; GENETICS; MITOCHONDRION; PATHOLOGY; TRANSGENIC MOUSE;

AGING; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIOXIDANTS; COGNITION DISORDERS; MALE; MICE; MICE, TRANSGENIC; MITOCHONDRIA; OLIGOPEPTIDES; SYNAPSES;

EID: 84960087719     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205013666151218150004     Document Type: Article

References (57)

1. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81(2): 741-766 (2001).
2. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60(8): 1119-1122 (2003).
3. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 8(7): 499-509 (2007).
4. Tanzi RE. The synaptic Abeta hypothesis of Alzheimer disease. Nat Neurosci 8(8): 977-979 (2005).
5. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 298(5594): 789-791 (2002).
6. Manczak M, Calkins MJ, Reddy PH. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Hum Mol Genet 20(13): 2495-2509 (2011).
7. Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304(5669): 448-452 (2004).
8. Du H, Guo L, Fang F, Chen D, Sosunov AA, McKhann GM, et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med 14(10): 1097-1105 (2008).
9. Wang X, Su B, Perry G, Smith MA, Zhu X. Insights into amyloid-beta-induced mitochondrial dysfunction in Alzheimer disease. Free Radic Biol Med 43(12): 1569-1573 (2007).
10. Benilova I, Karran E, De Strooper B. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 15(3): 349-357 (2012).
11. Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, Milner TA, et al. Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci 24(14): 3592-3599 (2004).
12. Zhao XL, Wang WA, Tan JX, Huang JK, Zhang X, Zhang BZ, et al. Expression of beta-amyloid induced age-dependent presynaptic and axonal changes in Drosophila. J Neurosci 30(4): 1512-1522 (2010).
13. Chan DC. Mitochondrial fusion and fission in mammals. Annu Rev Cell Dev Biol 22: 79-99 (2006).
14. Rojo M, Legros F, Chateau D, Lombes A. Membrane topology and mitochondrial targeting of mitofusins, ubiquitous mammalian homologs of the transmembrane GTPase Fzo. J Cell Sci 115(Pt 8): 1663-1674 (2002).
15. Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol 160(2): 189-200 (2003).
16. Santel A, Fuller MT. Control of mitochondrial morphology by a human mitofusin. J Cell Sci 114(Pt 5): 867-874 (2001).
17. Liu X, Weaver D, Shirihai O, Hajnoczky G. Mitochondrial 'kiss-and-run': interplay between mitochondrial motility and fusion-fission dynamics. EMBO J 28(20): 3074-3089 (2009).
18. Twig G, Graf SA, Wikstrom JD, Mohamed H, Haigh SE, Elorza A, et al. Tagging and tracking individual networks within a complex mitochondrial web with photoactivatable GFP. Am J Physiol Cell Physiol 291(1): C176-184 (2006).
19. Reddy PH. Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. Exp Neurol 218(2): 286-292 (2009).
20. Wu HY, Hudry E, Hashimoto T, Kuchibhotla K, Rozkalne A, Fan Z, et al. Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J Neurosci 30(7): 2636-2649 (2010).
21. Tampellini D, Gouras GK. Synapses, synaptic activity and intraneuronal abeta in Alzheimer's disease. Front Aging Neurosci 2(13): 5 (2010).
22. Du H, Guo L, Yan S, Sosunov AA, McKhann GM, Yan SS. Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc Natl Acad Sci USA 107(43): 18670-18675 (2010).
23. Wang X, Su B, Siedlak SL, Moreira PI, Fujioka H, Wang Y, et al. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci U S A 105(49): 19318-19323 (2008).
24. Knafo S, Alonso-Nanclares L, Gonzalez-Soriano J, Merino-Serrais P, Fernaud-Espinosa I, Ferrer I, et al. Widespread changes in dendritic spines in a model of Alzheimer's disease. Cereb Cortex 19(3): 586-592 (2009).
25. Carulli D, Buffo A, Strata P. Reparative mechanisms in the cerebellar cortex. Prog Neurobiol 72(6): 373-398 (2004).
26. Kaneda M, Nagashima M, Nunome T, Muramatsu T, Yamada Y, Kubo M, et al. Changes of phospho-growth-associated protein 43 (phospho-GAP43) in the zebrafish retina after optic nerve injury: a long-term observation. Neurosci Res 61(3): 281-288 (2008).
27. Migaud M, Charlesworth P, Dempster M, Webster LC, Watabe AM, Makhinson M, et al. Enhanced long-term potentiation and impaired learning in mice with mutant postsynaptic density-95 protein. Nature 396(6710): 433-439 (1998).
28. Janz R, Sudhof TC, Hammer RE, Unni V, Siegelbaum SA, Bolshakov VY. Essential roles in synaptic plasticity for synaptogyrin I and synaptophysin I. Neuron 24(3): 687-700 (1999).
29. Takeda T. Senescence-accelerated mouse (SAM): a biogerontological resource in aging research. Neurobiol Aging 20(2): 105-110 (1999).
30. Del Valle J, Duran-Vilaregut J, Manich G, Casadesus G, Smith MA, Camins A, et al. Early amyloid accumulation in the hippocampus of SAMP8 mice. J Alzheimers Dis 19(4): 1303-1315 (2010).
31. Takemura M, Nakamura S, Akiguchi I, Ueno M, Oka N, Ishikawa S, et al. Beta/A4 proteinlike immunoreactive granular structures in the brain of senescence-accelerated mouse. Am J Pathol 142(6): 1887-1897 (1993).
32. Takeda T. Senescence-accelerated mouse (SAM) with special references to neurodegeneration models, SAMP8 and SAMP10 mice. Neurochem Res 34(4): 639-659 (2009).
33. Shi YQ, Huang TW, Chen LM, Pan XD, Zhang J, Zhu YG, et al. Ginsenoside Rg1 attenuates amyloid-beta content, regulates PKA/CREB activity, and improves cognitive performance in SAMP8 mice. J Alzheimers Dis 19(3): 977-989 (2010).
34. Wang HM, Wang LW, Liu XM, Li CL, Xu SP, Farooq AD. Neuroprotective effects of forsythiaside on learning and memory deficits in senescence-accelerated mouse prone (SAMP8) mice. Pharmacol Biochem Behav 105: 134-141 (2013).
35. Dobarro M, Orejana L, Aguirre N, Ramirez MJ. Propranolol restores cognitive deficits and improves amyloid and Tau pathologies in a senescence-accelerated mouse model. Neuropharmacology 64: 137-144 (2013).
36. Tomobe K, Nomura Y. Neurochemistry, neuropathology, and heredity in SAMP8: a mouse model of senescence. Neurochem Res 34(4): 660-669 (2009).
37. Takeda T, Hosokawa M, Higuchi K, Hosono M, Akiguchi I, Katoh H. A novel murine model of aging, Senescence-Accelerated Mouse (SAM). Arch Gerontol Geriatr 19(2): 185-192 (1994).
38. Nomura Y, Okuma Y. Age-related defects in lifespan and learning ability in SAMP8 mice. Neurobiol Aging 20(2): 111-115 (1999).
39. Pasinetti GM. From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: the role of NSAIDs and cyclooxygenase in beta-amyloidosis and clinical dementia. J Alzheimers Dis 4(5): 435-445 (2002).
40. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21(21): 8370-8377 (2001).
41. Zhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW, et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem 279(33): 34682-34690 (2004).
42. Szeto HH. Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS J 8(2): E277-283 (2006).
43. Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 47: 629-656 (2007).
44. Szeto HH. Development of mitochondria-targeted aromatic-cationic peptides for neurodegenerative diseases. Ann N Y Acad Sci 1147: 112-121 (2008).
45. Cho S, Szeto HH, Kim E, Kim H, Tolhurst AT, Pinto JT. A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36. J Biol Chem 282(7): 4634-4642 (2007).
46. Thomas DA, Stauffer C, Zhao K, Yang H, Sharma VK, Szeto HH, et al. Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves posttransplantation function. J Am Soc Nephrol 18(1): 213-222 (2007).
47. Cho J, Won K, Wu D, Soong Y, Liu S, Szeto HH, et al. Potent mitochondria-targeted peptides reduce myocardial infarction in rats. Coron Artery Dis 18(3): 215-220 (2007).
48. Petri S, Kiaei M, Damiano M, Hiller A, Wille E, Manfredi G, et al. Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J Neurochem 98(4): 1141-1148 (2006).
49. Schiller PW, Nguyen TM, Berezowska I, Dupuis S, Weltrowska G, Chung NN, et al. Synthesis and in vitro opioid activity profiles of DALDA analogues. Eur J Med Chem 35(10): 895-901 (2000).
50. Guldner FH, Ingham CA. Increase in postsynaptic density material in optic target neurons of the rat suprachiasmatic nucleus after bilateral enucleation. Neurosci Lett 17(1-2): 27-31 (1980).
51. Jones DG, Devon RM. An ultrastructural study into the effects of pentobarbitone on synaptic organization. Brain Res 147(1): 47-63 (1978).
52. Hosokawa M, Kasai R, Higuchi K, Takeshita S, Shimizu K, Hamamoto H, et al. Grading score system: a method for evaluation of the degree of senescence in senescence accelerated mouse (SAM). Mech Ageing Dev 26(1): 91-102 (1984).
53. Manczak M, Mao P, Calkins MJ, Cornea A, Reddy AP, Murphy MP, et al. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J Alzheimers Dis 20 Suppl 2: S609-631 (2010).
54. Xiong K, Cai H, Luo XG, Struble RG, Clough RW, Yan XX. Mitochondrial respiratory inhibition and oxidative stress elevate beta-secretase (BACE1) proteins and activity in vivo in the rat retina. Exp Brain Res 181(3): 435-446 (2007).
55. Deng X, Li M, Ai W, He L, Lu D, Patrylo PR, et al. Lipolysaccharide-Induced Neuroinflammation Is Associated with Alzheimer-Like Amyloidogenic Axonal Pathology and Dendritic Degeneration in Rats. Adv Alzheimer Dis 3(2): 78-93 (2014).
56. Szeto HH, Liu S, Soong Y, Wu D, Darrah SF, Cheng FY, et al. Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. J Am Soc Nephrol 22(6): 1041-1052 (2011).
57. Mizuguchi Y, Chen J, Seshan SV, Poppas DP, Szeto HH, Felsen D. A novel cell-permeable antioxidant peptide decreases renal tubular apoptosis and damage in unilateral ureteral obstruction. Am J Physiol Renal Physiol 295(5): F1545-1553 (2008).